Navigation Links
Sunesis Pharmaceuticals Reports Data from Nonclinical Studies of SNS-032 at the Annual Meeting of the American Association for Cancer Research
Date:4/16/2008

SNS-032 Demonstrates Activity in Multiple Myeloma and Mantle Cell Lymphoma

SOUTH SAN FRANCISCO, Calif., April 16 /PRNewswire-FirstCall/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today reported data from nonclinical studies of SNS-032 in multiple myeloma and mantle cell lymphoma. Data from studies conducted in collaboration with the Multiple Myeloma Research Consortium (MMRC) and with the University of Texas MD Anderson Cancer Center were presented at the Annual Meeting of the American Association for Cancer Research (AACR) in San Diego, CA. SNS-032, a potent and selective inhibitor of cyclin-dependent kinases (CDKs) 2, 7 and 9, is currently in a Phase 1 clinical trial in patients with chronic lymphocytic leukemia (CLL) or multiple myeloma.

"Our collaborations with leading oncology thought leaders, such as Dr. Trudel and the MMRC Validation Team and Dr. Plunkett of MD Anderson Cancer Center, provide us with important new insights into SNS-032's activity in hematologic cancers," said Daniel C. Adelman, M.D., Senior Vice President, Development and Chief Medical Officer of Sunesis. "Results presented today from studies in primary and human cell lines demonstrate SNS-032's potential both alone and in combination with other agents in multiple myeloma and other B cell malignancies and further support our ongoing Phase 1 clinical trial."

An oral presentation by Suzanne Trudel, MSc, M.D., Assistant Professor, Princess Margaret Hospital, University Health Network in Toronto, Canada, focused on results from studies by the MMRC Validation Team, in collaboration with Sunesis scientists, of SNS-032 in human myeloma cell lines and primary multiple myeloma cells. SNS-032 demonstrated broad, mechanism-based activity in the human my
'/>"/>

SOURCE Sunesis Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Sunesis Pharmaceuticals to Present Non-Clinical Data at the Annual Meeting of the American Association for Cancer Research
2. Sunesis Pharmaceuticals Reports Positive Interim Data for SNS-595 Single-Agent Activity in Platinum-Resistant Ovarian Cancer
3. Sunesis Pharmaceuticals to Present Data on Two Product Candidates at the 49th Annual Meeting of the American Society of Hematology
4. Sunesis Pharmaceuticals Reports Preliminary SNS-595 Activity in Ovarian Cancer Clinical Trial at AACR-NCI-EORTC International Conference
5. Sunesis Pharmaceuticals Commences Clinical Trials of SNS-595 and SNS-314
6. Rib-X Pharmaceuticals Renews Collaborative Agreement with the Medical Research Council
7. Poniard Pharmaceuticals Oral Picoplatin Demonstrates Positive Bioavailability in Ongoing Phase 1 Trial
8. Antipodean Pharmaceuticals Announces Completion of Phase 2 Study of Lead Compound MitoQ(R)
9. Poniard Pharmaceuticals Announces Presentation of Clinical Data From Picoplatin Phase 2 Small Cell Lung Cancer Trial to be Presented at 1st IASLC-ESMO European Lung Cancer Conference
10. Alseres Pharmaceuticals, Inc. to Address a Congressional Briefing on Paralysis Research and the Spinal Cord Injury Community at Working 2 Walk in Washington, DC, April 13-15, 2008
11. Arena Pharmaceuticals Initiates Phase 2b Clinical Trial of APD125 for the Treatment of Insomnia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... VIEW, Calif. , July 29, 2014  Alexza ... that it is participating in two healthcare conferences during ... Conference and the Morgan Stanley Global Healthcare 2014 Conference. ... Morgan Stanley Conference.  The details on each event are ... Conference, Monday, August 11, 2014 in Boston ...
(Date:7/29/2014)... 2014  Covance Inc. (NYSE: CVD ) ... 30, 2014.  Net revenue was $639 million, representing 8.0% ... GAAP basis, the company reported earnings of $0.29 per ... pro forma earnings per diluted share of $0.95, up ... results exclude asset impairment charges totaling $52.6 million, or ...
(Date:7/29/2014)... , July 29, 2014 New technology ... which could allow physicians to see and assess brain ... promise, according to study authors who released their findings ... th Annual Meeting in Colorado Springs, ... advance the field of neurointervention, a specialty that facilitates ...
Breaking Medicine Technology:Alexza Pharmaceuticals Announces Participation in Upcoming Investor Conferences 2Alexza Pharmaceuticals Announces Participation in Upcoming Investor Conferences 3Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 2Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 3Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 4Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 5Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 6Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 7Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 8Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 9Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 10Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 11Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 12Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 13Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 14Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 15Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 16Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 17Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 18Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 19Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 20Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 21Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 22Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 23Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 24New Technology May Improve Visualization Of The Brain During Stroke Treatment 2New Technology May Improve Visualization Of The Brain During Stroke Treatment 3
... 2011 Reportlinker.com announces that a ... in its catalogue: ... Market 2011-2021 ... the commercial prospects for lyophilisation technology? ...
...  Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN ) today ... the 2011 Deutsche Bank BioFEST scheduled for Monday, December ... Eastern Time.  The session may be accessed through the ... Relations page.  An archived version of the presentation will ...
Cached Medicine Technology:Lyophilisation for Pharmaceuticals: Technology and Services Market 2011-2021 2Lyophilisation for Pharmaceuticals: Technology and Services Market 2011-2021 3Lyophilisation for Pharmaceuticals: Technology and Services Market 2011-2021 4Lyophilisation for Pharmaceuticals: Technology and Services Market 2011-2021 5Lyophilisation for Pharmaceuticals: Technology and Services Market 2011-2021 6Lyophilisation for Pharmaceuticals: Technology and Services Market 2011-2021 7Lyophilisation for Pharmaceuticals: Technology and Services Market 2011-2021 8Lyophilisation for Pharmaceuticals: Technology and Services Market 2011-2021 9Lyophilisation for Pharmaceuticals: Technology and Services Market 2011-2021 10Lyophilisation for Pharmaceuticals: Technology and Services Market 2011-2021 11Lyophilisation for Pharmaceuticals: Technology and Services Market 2011-2021 12Lyophilisation for Pharmaceuticals: Technology and Services Market 2011-2021 13Regeneron Announces Presentation Time Change at the 2011 Deutsche Bank BioFEST 2
(Date:7/30/2014)... Seattle, WA (PRWEB) July 30, 2014 According ... by Vkool.com, this is a comprehensive guide that teaches people ... a few weeks. The book uncovers to readers the horrible ... writes in its review that inside this book, people will ... such as inflammation, asthma, and nasal infections. , Nasal ...
(Date:7/30/2014)... 30, 2014 pMD, the leading ... launched an Observation Result (ORU) interface to streamline ... cardiology customers are using the ORU interface to ... test interpretations for electrocardiograms, echocardiograms, and stress tests. ... hospital, the cardiology system produces electronic data for ...
(Date:7/29/2014)... July 29, 2014 Paul Mata, CEO of ... More Money in 30 Days” E-book. The e-book includes a ... to make extra cash. Examples include downloading and utilizing specific ... websites that help people monetize the assets they didn't know ... items they can find in their garage. , After ...
(Date:7/29/2014)... 2014 Dignity Sciences Limited, a privately ... a Phase I trial with DS107G, an oral formulation ... was a randomized, placebo-controlled, double-blind, single-ascending and multiple dose ... and effect of food on DS107G in healthy subjects. ... of DGLA following both single and multiple oral doses ...
(Date:7/29/2014)... Use of electroacupuncture (EA) a form of ... between pairs of acupuncture needles produces significant ... little as eight weeks for early stage breast ... use of aromatase inhibitors (AIs) to treat breast ... examining the intervention led by researchers at the ...
Breaking Medicine News(10 mins):Health News:Nasal Polyps Treatment Miracle Book Review Exposes Manuel Richards' Guide For Treating Nasal Polyps – Vkool.com 2Health News:Nasal Polyps Treatment Miracle Book Review Exposes Manuel Richards' Guide For Treating Nasal Polyps – Vkool.com 3Health News:pMD Automates Cardiology Charge Capture: Low-Reimbursement Services Become Profitable 2Health News:pMD Automates Cardiology Charge Capture: Low-Reimbursement Services Become Profitable 3Health News:Create Indestructible Wealth Launches Innovative E-Book: “Realistic Ways to Make More Money in 30 Days” 2Health News:DS107G-01 – Successful Completion of Phase I Oral DGLA Clinical Trial 2Health News:Acupuncture improves quality of life for breast cancer patients using aromatase inhibitors 2Health News:Acupuncture improves quality of life for breast cancer patients using aromatase inhibitors 3
... of Women’s Heart Health by setting up 100 chest pain ... clinics will be spread across the country. // ... Hospitals, spoke of Apollo’s plan to set up chest pain ... (ACE), as it is called, will comprise of the chest ...
... Eating a healthy die is very essential to maintain ... rich in nutrients such as fruits and vegetables along ... prevents chronic diseases like cancer, diabetes, obesity and hypertension. ... present in lean meats, eggs, beans, nuts and they ...
... about AIDS/HIV, the Rotarians of Malda and the district ... program// ('One step for awareness about HIV-AIDS') in the ... ,The local barbers, under the guidance of the organizing ... was conducted at Rotary Bhawan. The heath officials projected ...
... that whole-grain foods keep triglycerides in their limits and keep ... Agricultural Research// Service scientists in California provides the know-how as ... chemist Nancy L. Keim, "Lipoproteins are the body's means of ... to fatty tissue, where they're stored as reserves.” ,It ...
... tight spot after it was suggested that , one ... be poor cabin air quality//.DVT is not caused by mere ... who suggest that cabin air quality may also play a ... journal seems to throw up plausible risk factors risk factors. ...
... a major role in reducing the bad cholesterol. For example ... Canadian researchers said that by combining these food substances one ... such diet as they are at a higher risk of ... the bad cholesterol (LDL) as effectively as a commonly prescribed ...
Cached Medicine News:Health News:A Complete Diet for Kids 2Health News:Fat fighters’: Whole-grain foods’: under the microsco 2Health News:Poor Quality of Cabin Air in the Plane Can Cause DVT, After A Long Flight 2Health News:Choose Foods That Keep Bad Cholesterol at Bay 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: